Q-omics provides the consensus-scored GHRHR profile across patient tissues and cancer cell-line models. GHRHR expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GHRHR is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, GHRHR RNA expression shows 8,541 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, KIRC, and ESCA as cancer lineages where GHRHR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GHRHR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GHRHR survival associations across molecular data types. GHRHR RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GHRHR RNA expression–survival associations across cancer types. High GHRHR expression shows unfavorable associations in THCA, KIRC and SKCM, but favorable associations in MESO, KIRP and LGG. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for GHRHR RNA expression.
This table summarizes GHRHR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GHRHR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GHRHR shows lower tumor expression in KIRC, KIRP, KICH, LUSC and LUAD and higher tumor expression in LIHC. The KIRC box plot shows higher GHRHR RNA expression in normal versus tumor tissue (log2 FC = −0.187, t-test p < 0.001).
This table shows molecular features associated with GHRHR in patient tissues and cancer cell lines. In patient samples, GHRHR shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, GHRHR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
